

RESOLUTION

Subject: Collaborative Drug Therapy Management
Submitted by: Michael Kuduk, MD (KMA Past President)
Referred to: Reference Committee

WHEREAS, physicians possess expertise in generating differential diagnoses, creating effective diagnostic and therapeutic plans, and utilization of deductive medical reasoning; and

WHEREAS, pharmacists possess expertise in pharmacology, pharmacokinetics, drug-drug interactions, and the ability to monitor ongoing therapy; and

WHEREAS, evidence shows that well designed collaborative drug therapy management programs utilize both physicians' and pharmacists' expertise to improve patient care (CDC August 2005); and

WHEREAS, evidence shows that physician-led team based care results in improved patient care outcomes and improved provider well-being (ACP Position Paper, 2025); now, therefore, be it

RESOLVED, that KMA support legislation which establishes and maintains physician-led collaborative drug therapy management programs, which allow monitoring, modifying and discontinuing of a patient's drug therapy by an authorized pharmacist under the supervision of a physician in accordance with a collaborative practice agreement and which do not have a diagnostic component; and be it further

RESOLVED, that KMA oppose legislation which establishes and maintains collaborative drug therapy management programs which are not physician led, possess a diagnostic component, or which create a separate provider-physician relationship.